To be a shareholder of record, investors are advised to own Biocept stock by 4:00 PM ET, Thursday, July 19, 2018 to account for T+2 settlement timing Record date established as Monday, July 23, 2018 SAN DIEGO , July 19, 2018 /PRNewswire/ -- Biocept, Inc.
Clinical studies with Biocept's Target Selector™ to evaluate the use of circulating tumor cells in disease assessment, surveillance and monitoring SAN DIEGO , July 23, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide
Expands intellectual property to 27 issued patents globally for highly sensitive methods of detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs) SAN DIEGO , July 31, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of
Further expands global patent estate for capturing and detecting biological targets of interest including rare cells such as circulating tumor cells (CTCs) SAN DIEGO , Aug. 2, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to
Biocept's Target Selector™ to be used in profiling and monitoring patients diagnosed with non-small cell lung cancer throughout an integrated healthcare delivery system SAN DIEGO , Aug. 6, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests
SAN DIEGO , Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announced today that the Company's previously announced
SAN DIEGO , Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial
Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , Aug. 14, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer
Allegheny Health Network's Cancer Institute spearheading the evaluation PITTSBURGH and SAN DIEGO , Aug. 23, 2018 /PRNewswire/ -- Highmark Health announced today that through its VITAL Innovation Program, it is testing Biocept, Inc.'s Target Selector™ liquid biopsy platform designed to help
Clinical study data highlight the ability of Biocept's proprietary liquid biopsy technology to detect and monitor actionable biomarkers and circulating tumor cell counts in the blood and in cerebrospinal fluid of non-small cell lung cancer patients SAN DIEGO , Sept.
